Three-quarters of stroke patients in a Swiss registry had at least 1 undiagnosed risk factor at the time of the event, most commonly hyperlipidemia or hypertension.
Statin-treated patients at high atherosclerotic risk experienced significantly slower progression of arterial stiffness vs those not taking statins in a cohort of more than 5000 patients.
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.
Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.
Black patients hospitalized with atrial fibrillation were 25% less likely to receive oral anticoagulants upon discharge according to a large national registry study.
USPSTF states low-dose aspirin should be considered for CVD prevention on a case-by-case basis in adults aged 40-59 yrs with a 10% or greater 10-year CVD risk.
Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.
The FDA clearance for the FitBit algorithm will provide another widely tested tool for patient and clinicians to help identify arrhythmias earlier and avoid severe cardiocerebrovascular events.
ACC 2022. Large study of US adults showed those with depression following MI were 50% more likely to experience a stroke than those who did not have depression.